Skip to main content
TipRanks
Go Ultimate75% OFF

IDT Australia Limited (IDT) AI Stock Analysis

4 Followers
AU:IDT

IDT Australia Limited

(ASX:IDT)

Select Model
Rating:42Neutral
Price Target:AUD 0.04â–²(2.94% Upside)
Action:reiterated
Date:11/07/26

The score is held back primarily by financial fundamentals: IDT remains loss-making with sharply compressed gross margins, a shrinking equity base and rapidly increased debt, even though revenue growth, narrowing losses and a swing to positive operating cash flow show genuine progress. Technicals reinforce the caution, with the price below all key moving averages and negative MACD momentum, while the negative P/E and absence of any dividend leave no valuation or income support. A sustained move to profitability and positive free cash flow would be needed to lift the score meaningfully.

Positive Factors
Revenue RecoveryRevenue's recovery from A$6.9m in 2023 to A$20.4m in 2026, including 7.12% year-on-year growth, indicates restored activity in IDT's contract services. If sustained, this larger revenue base can improve capacity utilization and provide a foundation for future operating leverage.
Negative Factors
Persistent LossesDespite the revenue rebound, IDT remained loss-making in 2026, with a net margin of -13.35% and EBIT margin of -8.09%. Persistent negative profitability limits internally generated capital, weakens resilience if activity softens, and shows that growth has not yet translated into sustainable earnings.

IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)

-50%-40%-30%-20%-10%0%10%20%30%AU:IDT-40.35%EWA+17.02%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 14.56M
Dividend Yield
―
Average Volume (3M)
221.06K
Price to Earnings (P/E)
-5.3
Beta (1Y)
1.54
Revenue Growth
5.93%
EPS Growth
66.32%
Country
Australia
Employees
156
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

IDT Australia Limited Business Overview & Revenue Model

Company Description

IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and fin...

How the Company Makes Money

IDT primarily makes money by providing contract services to pharmaceutical and healthcare companies, earning revenue from fees charged for manufacturing and related services delivered under customer contracts. Key revenue streams typically include (w...

IDT Australia Limited Financial Statement Overview

Summary

IDT Australia is an early-stage turnaround. Revenue has more than tripled since FY2023 to about $20.4m, losses have narrowed sharply (net loss down to $2.7m from $8.1m, EBITDA near breakeven) and operating cash flow has flipped positive at $1.1m after three years of heavy burn. However, the company remains unprofitable with a -13% net margin, gross margin collapsed to roughly 21% from 49%, free cash flow is still slightly negative, equity has eroded to $19.0m, and debt has jumped from under $1m to about $10.8m, lifting debt-to-equity to 0.57. The direction of travel is encouraging but the financial profile is still that of a sub-scale, cash-tight manufacturer.

Income Statement

36Negative

Balance Sheet

49Neutral

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue20.36M20.36M19.77M13.23M6.93M12.11M
Gross Profit4.29M4.29M9.69M10.42M-3.53M2.82M
EBITDA-743.00K-743.00K-6.54M-5.56M-8.83M-340.00K
Net Income-2.72M-2.72M-8.06M-5.41M-8.50M-1.16M
Balance Sheet
Total Assets34.89M34.89M36.92M31.37M28.29M30.08M
Cash, Cash Equivalents and Short-Term Investments2.52M2.52M4.11M904.00K4.43M9.21M
Total Debt10.82M10.82M10.40M4.47M740.00K881.00K
Total Liabilities15.85M15.85M15.03M7.93M4.15M3.46M
Stockholders Equity19.04M19.04M21.89M23.44M24.14M26.63M
Cash Flow
Free Cash Flow-243.00K-243.00K-7.55M-10.30M-8.42M1.95M
Operating Cash Flow1.07M1.07M-6.25M-9.60M-7.90M2.86M
Investing Cash Flow2.19M2.19M-4.50M-1.09M-522.00K-912.00K
Financing Cash Flow-1.25M-1.25M10.75M6.77M3.64M337.00K

IDT Australia Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.03

Price Trends

50DMA0.04Negative
100DMA0.04Negative
200DMA0.04Negative

Market Momentum

MACD-0.00Positive
RSI24.47Positive
STOCH-25.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 24.47 is Positive, neither overbought nor oversold. The STOCH value of -25.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.

IDT Australia Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:IDT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:VLSAU:VLS82OutperformAUD 141.68M13.3819.91%5.49%12.19%22.36%
AU:MVPAU:MVP57NeutralAUD 48.44M73.211.13%―8.99%450.00%
AU:CANAU:CAN53NeutralAUD 8.30M0.3664.70%―-24.22%―
AU:LGPAU:LGP52NeutralAUD 57.13M-15.22-1.67%―15.21%-141.82%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:IDTAU:IDT42NeutralAUD 14.06M-5.31-13.81%―5.93%66.32%
AU:PKPAU:PKP39UnderperformAUD 18.75M-5.074388.00%―-19.73%50.34%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%AU:IDTAU:CANAU:VLSAU:LGPAU:MVPAU:PKPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:IDT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:IDTIDT Australia Limited0.03-0.02-41.38%
AU:CANCann Group Ltd.0.01-0.00-9.09%
AU:VLSVita Life Sciences Limited2.640.3716.35%
AU:LGPLittle Green Pharma Ltd.0.07-0.06-46.92%
AU:MVPMedical Developments International Limited0.43-0.13-23.21%
AU:PKPAlthea Group Holdings Ltd.0.01-0.01-30.00%

IDT Australia Limited Corporate Events

IDT Australia Plans Issue of 6 Million Options to Bolster Capital Flexibility

Oct 23, 2026

IDT Australia Limited has notified the ASX of a proposed issue of up to 6 million options, each expiring on various dates and with differing exercise prices, under a placement or similar type of securities issue. The options are scheduled for issue o...

IDT Australia Issues 14.3 Million Unquoted Performance Rights Under Incentive Scheme

Oct 23, 2026

IDT Australia Limited has notified the market of the issue of 14,300,000 unquoted performance rights under its employee incentive scheme, effective October 23, 2026. The new rights, which are not intended to be quoted on the ASX, signal the company’s...

IDT Australia Issues New Shares Under Employee Performance Rights Plan

Oct 5, 2026

IDT Australia Limited has issued 1,388,545 fully paid ordinary shares to employees following the exercise of performance rights under its Employee Performance Rights Plan. The issue, completed on 2 October 2026, reflects ongoing use of equity-based i...

IDT Australia Expands Listed Capital with New Share Quotation

Oct 5, 2026

IDT Australia Limited has applied for quotation of 1,388,545 new ordinary fully paid shares on the ASX, with the securities issued on 02 October 2026. The application reflects an increase in the company’s listed capital base, which may support its on...

IDT Australia Issues 2.7 Million Unquoted Performance Rights

Sep 2, 2026

IDT Australia Limited has notified the market of the issue of 2,711,096 unquoted performance rights under its employee incentive scheme.The performance rights, which are not intended to be quoted on the ASX, were issued on 28 August 2026 and reflect...

IDT Australia Seeks ASX Quotation for Employee Incentive Share Issue

Sep 2, 2026

IDT Australia Limited has applied for ASX quotation of 1,166,655 fully paid ordinary shares issued to employees as a short‑term incentive at nil consideration. The shares, allotted on August 28, 2026 under the company’s LR7.1 placement capacity, are...

IDT Australia moves to reassure investors after delayed director share notice

Aug 24, 2026

IDT Australia Limited has disclosed a change in director Geoffrey Sam’s shareholding, filing an updated notice with the ASX to reflect an equity transaction that occurred on 12 May 2026. The company attributed the delay in lodging the notice to an in...

IDT Australia Outlines FY26 Results and Investment Risk Framework

Aug 20, 2026

IDT Australia Limited has released its full‑year FY26 results presentation, framed around its strategy of advanced manufacturing for breakthrough medicines. The document serves as a high‑level overview of the company’s operations and financial contex...

IDT Australia Narrows Losses and Invests to Capture CDMO Growth

Aug 20, 2026

IDT Australia has reported a sharp improvement in its fiscal 2026 performance as a strategic reset lifts earnings and reshapes its revenue mix. EBITDA loss narrowed by 85% to $0.9 million, while revenue from its three core verticals – APIs, specialty...

IDT Australia Narrows Annual Loss as Revenue Edges Higher

Aug 20, 2026

IDT Australia Limited reported a 3.4% increase in revenues and other income to $20.53 million for the year ended 30 June 2026, while significantly narrowing its after-tax loss to $2.72 million from $8.06 million a year earlier. The company did not de...

IDT Australia Director’s Options Expire, Shareholding Unchanged

Aug 10, 2026

IDT Australia Limited has disclosed a change in director Mark Simari’s interests, with 6,000,000 unlisted options previously held indirectly through associated entities expiring without consideration. Following this change, Simari’s indirect holding...

IDT Australia Director’s Options Expire, Shareholdings Unchanged

Aug 10, 2026

IDT Australia Limited has disclosed a change in the interests of director Geoffrey Sam following the expiry of unlisted options held indirectly through family-related entities. Sam’s indirect holding of 3,000,000 unlisted options has lapsed with no c...

IDT Australia Options Lapse, Simplifying Capital Structure

Aug 10, 2026

IDT Australia Limited has confirmed the lapse of 12,000,000 listed options, which expired unexercised on 7 August 2026, resulting in the cessation of these securities. The expiry slightly simplifies the company’s capital structure, with no immediate...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026